PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, regardless of regimen and dose compared with 10 days (moderate certainty).
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, PCA subgroup compared with 10 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in H.pylori persistence, PAN subgroup compared with 10 days (low certainty).
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in H. pylori persistence, PCN subgroup compared with 7 days (low certainty).
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PAN subgroup compared with 7 days (moderate certainty).
PPI triple therapy for 14 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PCN subgroup compared with 7 days (very low certainty).
It is very uncertain whether brushed less than twice per day changes fluorosis (percentage prevalence in permanent teeth) compared with brushed twice or more per day (very low certainty).
14 days on/off antibiotic regimen probably leads to lower exacerbation frequency compared with 14 days on/off placebo regimen (moderate certainty).
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
28 days on/off antibiotic regimen leads to higher antibiotic resistance compared with 28 days on/off placebo regimen (high certainty).
28 days on/off antibiotic regimen showed no clear difference in hospitalisation for pulmonary exacerbations compared with 28 days on/off placebo regimen (high certainty).
14 days on/off antibiotic regimen showed no clear difference in exacerbation frequency compared with 28 days on/off antibiotic regimen (moderate certainty).